Global Custom Market Research Reports Provider Company

phone

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2018

  • Published Date: 12 Jun 2018
  • Number of Pages: 91
  • Category: Pharmaceuticals
  • Country: Global
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2018, provides an overview of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline landscape.

Hereditary angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing and difficulty breathing. Treatment includes medications, such as epinephrine, antihistamines, and corticosteroids.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, Preclinical and Discovery stages are 4, 1, 5, 9 and 1 respectively.

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology).
- The pipeline guide reviews pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development
Adverum Biotechnologies Inc
BioCryst Pharmaceuticals Inc
Cevec Pharmaceuticals GmbH
CSL Ltd
iBio Inc
Ionis Pharmaceuticals Inc
Kalvista Pharmaceuticals Inc
Pharming Group NV
ProMetic Life Sciences Inc
Rezolute Inc
Shire Plc
Verseon Corp
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drug Profiles
ADVM-053 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATN-035 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATN-249 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCX-7353 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (recombinant) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (recombinant) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1-esterase inhibitor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSL-312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
icatibant acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-PKKLRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-PKKRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KVD-818 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KVD-900 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KVD-XXX - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanadelumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RZ-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Product Development Milestones
Featured News & Press Releases
May 29, 2018: BioCryst Announces Presentation of Additional Analyses of the APeX-1 Clinical Trial of BCX7353 at the 2018 European Academy of Allergy and Clinical Immunology (EAACI) Congress
May 29, 2018: KalVista Pharmaceuticals Presents Data at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018
May 24, 2018: BioCrysts BCX7353 Receives European Regulatory Designations for the Treatment of Hereditary Angioedema
Apr 18, 2018: The Swiss Agency for Therapeutic Products (Swissmedic) Validates Shires Marketing Authorization Application for Investigational Hereditary Angioedema Treatment Lanadelumab
Mar 29, 2018: Shire Reports Regulatory Milestones for Investigational Hereditary Angioedema Treatment Lanadelumab
Mar 15, 2018: BioCryst Announces Initiation of the Phase 3 APeX-2 Trial of BCX7353 in Patients with Hereditary Angioedema
Mar 15, 2018: CSL Behring Receives Patient Impact Award For Subcutaneous Prophylactic Treatment To Prevent Hereditary Angioedema Attacks
Mar 03, 2018: New Data from Pivotal Phase 3 Study Investigating Lanadelumab as a Prophylactic Treatment for Hereditary Angioedema to be Presented at 2018 AAAAI/WAO Joint Congress
Feb 28, 2018: BioCryst Announces Initiation of the APeX-S Long-Term Safety Trial of BCX7353 in Patients with Hereditary Angioedema
Feb 27, 2018: The European Medicines Agency Grants Accelerated Assessment for Shires Lanadelumab Being Evaluated for the Prevention of Attacks in Hereditary Angioedema Patients Aged 12 Years and Older
Feb 23, 2018: FDA Accepts Shire Biologics License Application (BLA) and Grants Priority Review for Lanadelumab for the Prevention of Attacks in Hereditary Angioedema (HAE) Patients
Feb 15, 2018: Shire Announces FDA Acceptance of sBLA for CINRYZE (C1 esterase inhibitor [human]) for Pediatric Hereditary Angioedema Use
Feb 13, 2018: Shire Provides Regulatory Progress Update On Lanadelumab
Jan 17, 2018: Pharming announces FDA Acceptance for Review of Supplemental Biologics License Application for RUCONEST for Prophylaxis of Hereditary Angioedema Attacks
Jan 10, 2018: Verseon presents hereditary angioedema program at Biotech Showcase
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Adverum Biotechnologies Inc, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by BioCryst Pharmaceuticals Inc, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Cevec Pharmaceuticals GmbH, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by CSL Ltd, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by iBio Inc, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Ionis Pharmaceuticals Inc, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Kalvista Pharmaceuticals Inc, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Pharming Group NV, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by ProMetic Life Sciences Inc, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Rezolute Inc, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Shire Plc, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Verseon Corp, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects, H1 2018
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products, H1 2018

List Of Figures

List of Figures
Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2018 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)

View Report

Lebers Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H1 2018 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Lebers Hereditary Optic Neuropathy (LHON) (Leber optic atrophy)

View Report

DelveInsights Hereditary Angioedema - Market Insight, Epidemiology and Market Forecast - 2027 report provides a detailed analysis of the Hereditary Angioedema epidemiology and market outlook for

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports